Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Acquisitions & Divestments: 2014-2024

Historic Change in Acquisitions & Divestments for Aclaris Therapeutics (ACRS) over the last 11 years, with Dec 2024 value amounting to $86.1 million.

  • Aclaris Therapeutics' Change in Acquisitions & Divestments rose 11.20% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 19.49%. This contributed to the annual value of $86.1 million for FY2024, which is 52.98% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Change in Acquisitions & Divestments is $86.1 million, which was down 52.98% from $183.2 million recorded in FY2023.
  • Aclaris Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $183.2 million during FY2023, with a 5-year trough of $54.6 million in FY2020.
  • Its 3-year average for Change in Acquisitions & Divestments is $149.1 million, with a median of $178.0 million in 2022.
  • As far as peak fluctuations go, Aclaris Therapeutics' Change in Acquisitions & Divestments plummeted by 74.08% in 2020, and later surged by 162.40% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $54.6 million in 2020, then climbed by 24.33% to $67.8 million in 2021, then skyrocketed by 162.40% to $178.0 million in 2022, then grew by 2.93% to $183.2 million in 2023, then plummeted by 52.98% to $86.1 million in 2024.